Volume 124, Issue 2 , Pages 328-336.e6, August 2009
Relevance of IgE binding to short peptides for the allergenic activity of food allergens
Background
Analysis of IgE antibody binding to epitopes provides information for food allergy diagnosis and management and construction of hypoallergenic candidate vaccines, but the contribution of sequential epitopes to functionally relevant IgE binding is not fully understood.
Objectives
We sought to study the impact of IgE-binding peptides described as major sequence epitopes in the literature on IgE-binding capacity of 2 selected food allergens.
Methods
IgE-binding peptides of the food allergens Ara h 2 (peanut) and Pen a 1 (shrimp) were identified. Synthetic soluble peptides representing the identified sequences were assessed for their capacity to inhibit IgE binding to the parent allergens by means of ELISA and in mediator release assay. The IgE-binding capacity of unfolded recombinant (r) Ara h 2 was analyzed. A hybrid tropomyosin carrying the IgE-binding regions of Pen a 1 grafted into the structural context of the nonallergenic mouse tropomyosin was applied in ELISA inhibition experiments and ImmunoCAP analysis.
Results
Although IgE-binding peptides representing sections of the allergen sequences were detected, no relevant capacity to inhibit the IgE binding to the parent allergen in ELISA or basophil activation test was observed. Unfolded rAra h 2 showed reduced IgE-binding capacity compared with folded rAra h 2 and failed to elicit mediator release. Hybrid tropomyosin bound less IgE than rPen a 1 in ImmunoCAP analysis and revealed marginal inhibitory capacity.
Conclusion
Peptides identified as major sequence epitopes on Pen a 1 and Ara h 2 show little contribution to the IgE binding of the allergens studied.
Key words: SPOT technique, B-cell epitopes, allergy, Pen a 1, Ara h 2, IgE binding
Abbreviations used: CD, Circular dichroism, MRW, Mean residue weight, r, Recombinant, RBL, Rat basophilic leukemia, red/alk, Reduced and alkylated
Supported by Paul-Ehrlich-Institut, Langen, Germany.
Disclosure of potential conflict of interest: A. Reuter has received research support from the Research Fund of the German Food Industry. J. Lidholm is an employee of Phadia AB. S. Vieths is an associate of the Institute for Product Quality; has received honoraria from the Phadia AB and the Food Allergy Resource and Research Program; is a consultant for Mars Chocolate UK Ltd; has received research support from the European Union, the German Research Foundation, the Research Fund of the German Food Industry, Monsanto, Pioneer Hi-Bred International Inc, the Food Allergy Resource and Research Program, and the European Directorate for the Quality of Medicines and Health Care; and holds positions with the European Academy of Allergy and Clinical Immunology, the International Union of Immunological Societies, the European Agency for the Evaluation of Medicinal Products, the European Pharmacopoeia Commission, International Life Science Institut (ILSI) Health and Environmental Science Institute, Comité Européen de Normalisation (CEN), and the German Society for Allergy and Clinical Immunology. T. Holzhauser has received research support from the European Commission. The rest of the authors have declared that they have no conflict of interest.
PII: S0091-6749(09)00855-0
doi:10.1016/j.jaci.2009.05.031
© 2009 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
Volume 124, Issue 2 , Pages 328-336.e6, August 2009
